FDA Approves Oral Suspension Form of Raltegravir
“On December 20, 2013, FDA approved a new dosage form, ISENTRESS® (raltegravir) for oral suspension, in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 4 weeks of age and older, weighing at least 3 kg to less than 20 kg. This also includes a new Instructions for Use document as part of the patient labeling.”
The updated labeling will be available at the FDA website.
More information is available:
AIDSinfo Mobile Guidelines Development: Reaching HIV Practitioners at the Point of Care
Exhibits on display at the recent 5th annual mHealth Summit included a poster tracing AIDSinfo’s ongoing efforts to develop mobile HIV/AIDS medical practice guidelines. The poster depicts how AIDSinfo is responding to rapid advances in technology to meet the increasing expectation for access to HIV-related information at the point of care (i.e., via tablets and smartphones). AIDSinfo mobile guidelines development is propelled by a 10-fold increase in mobile traffic to AIDSinfo over the past 3 years, as well as research that shows that 90% of health care providers surveyed on the AIDSinfo website have Internet access at the point of care.
Click here to view the poster, which is posted in the Health Topics section of the AIDSinfo website.